Peptide A · Melanocortin analogues
PT-141 (Bremelanotide)
Synthetic melanocortin-receptor agonist research material
PT 141BremelanotideVyleesi
Open the 10 mg price board ↗Research price & evidence comparisonPT-141 (Bremelanotide)
PT-141 (Bremelanotide)
vs Melanotan II.
PT-141 and Melanotan II share melanocortin-related catalog language and can appear beside one another on research seller sites. This comparison separates their exact identities, aliases, 10 mg price boards, seller overlap, availability, and public evidence routes - and keeps the approved Vyleesi medicine record outside the research-market ranking.
2shared seller pages
Same10 mg / 10 mg board sizes
4rows with public evidence routes
0clinical or effect rankings
Identity before price
Two records, kept separate.
PT-141 is categorized as a synthetic melanocortin-receptor agonist research material and is also searched as bremelanotide; Melanotan II is categorized as a synthetic cyclic melanocortin analogue research material. Similar family language does not make the seller-labelled vials or evidence records interchangeable.
Peptide B · Melanocortin analogues
Melanotan II
Synthetic cyclic melanocortin analogue research material
MT-IIMT2Melanotan 2
Open the 10 mg price board ↗Like-for-like fields
Commercial footprint, side by side.
Price ranges use rows marked in stock. “Public evidence route” means a seller exposed a document link; it does not establish authenticity, chain of custody, purity, sterility, or vial contents.
| Comparison field | PT-141 (Bremelanotide) | Melanotan II |
|---|---|---|
| Editorial family | Melanocortin analogues | Melanocortin analogues |
| Seller-listed identity | Synthetic melanocortin-receptor agonist research material | Synthetic cyclic melanocortin analogue research material |
| Nominal board size | 10 mg | 10 mg |
| Available list range | $45.00–$47.29 | $36.99–$36.99 |
| Median available price | $46.14 | $36.99 |
| Lowest available / mg | $4.50 | $3.70 |
| Available rows | 2 of 3 | 1 of 3 |
| Public evidence routes | 2 rows | 2 rows |
| Evidence only on request | 1 rows | 1 rows |
| Available-price spread | 5% | 0% |
| Snapshot checked | Jul 23, 2026 | Jul 23, 2026 |
Unit warning
Per-milligram figures normalize the seller’s nominal quantity only. They are not a cross-compound value, potency, effect, or dose comparison.
Seller overlap
Where the current boards intersect.
The search is an identity trap because PT-141 connects by ingredient name to an approved medicine record while Melanotan II remains a separate research-market entity. A useful comparison must preserve all three lanes.
- Core Peptides
- Pepta Labs
- Biotech Peptides
- Purgo Labs
Three reading rules
What keeps this comparison honest.
- 01
Open the Vyleesi record for the exact FDA-approved product rather than transferring approval to a PT-141 vial.
- 02
Compare the two research boards only on their observable commercial and evidence-access fields.
- 03
Do not interpret shared melanocortin terminology as proof of equivalent route, presentation, safety, or use.
Official context boundary
Read the source behind each category note.
These official context records explain why Peptide Local keeps research listings outside medical and approved-product lanes. They do not certify any seller or material.
Bremelanotide is the active ingredient in FDA-approved Vyleesi, but that prescription product has a specific 1.75 mg presentation, indication, label, and regulated supply chain. These 10 mg research listings are not approval-equivalent.
Read the current DailyMed drug label ↗FDA lists Melanotan II among bulk substances that may present significant safety risks in compounding and describes reports of serious adverse events plus insufficient information to establish safety for human administration.
Read the FDA source ↗Continue comparing